Efficacy and safety of dupilumab in the treatment of 21 cases of bullous pemphigoid: a retrospective study
- VernacularTitle:度普利尤单抗治疗大疱性类天疱疮21例的疗效及安全性回顾分析
- Author:
Liuqi ZHAO
1
;
Yan CHEN
;
Danyang CHEN
;
Birao FAN
;
Rui WANG
;
Panpan SHANG
;
Xixue CHEN
;
Xuejun ZHU
;
Mingyue WANG
Author Information
- Keywords: Pemphigoid, bullous; Biological agents; Therapy; Eosinophils; Immunoglobulin E; Dupilumab
- From: Chinese Journal of Dermatology 2022;55(6):480-485
- CountryChina
- Language:Chinese
- Abstract: Objective:To retrospectively analyze the efficacy and safety of dupilumab in the treatment of bullous pemphigoid (BP) .Methods:Clinical data were collected from BP patients who received injections of dupilumab at an initial dose of 600 mg followed by an every-2-week regimen at a dose of 300 mg (the frequency of injections could be increased if necessary) in Department of Dermatology, Peking University First Hospital from October 2020 to October 2021, and their clinical manifestations and changes in laboratory indices were analyzed.Results:A total of 21 BP patients treated with dupilumab were included in this study. Nineteen (90.5%) patients achieved complete or marked disease control after 2-week treatment with dupilumab; 12 patients were followed up for 16 weeks, and all maintained complete disease control at 16 weeks. All patients had a bullous pemphigoid disease area index (BPDAI) score of 122.5 ± 51.1 points at baseline, which decreased to 30.6 ± 27.4 points after 2-week treatment with dupilumab ( t = 8.53, P < 0.001) , and continued to decrease to 12.7 ± 9.1 points after 4-week treatment ( t = 9.73, P < 0.001) . Pruritus was markedly relieved in all the 21 patients within 4-week treatment with dupilumab. Among 10 patients with elevated eosinophil counts at baseline, the eosinophil counts markedly decreased in 9 after treatment. The serum IgE level was elevated in 7 patients at baseline, which markedly decreased in 6 after treatment. Viral conjunctivitis occurred in 1 (4.8%) patient, and no adverse reactions were observed in other patients. Conclusion:Dupilumab is effective in the control of BP and relief of pruritus, with a favorable safety profile.
